BACKGROUND: The significance of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) is unknown. Using a multinational collection of isolates from methicillin-resistant S. aureus (MRSA) infective endocarditis (IE), we characterized patients with IE with and without hVISA, and we genotyped the infecting strains. METHODS: MRSA bloodstream isolates from 65 patients with definite IE from 8 countries underwent polymerase chain reaction (PCR) for 31 virulence genes, pulsed-field gel electrophoresis, and multilocus sequence typing. hVISA was defined using population analysis profiling. RESULTS: Nineteen (29.2%) of 65 MRSA IE isolates exhibited the hVISA phenotype by population analysis profiling. Isolates from Oceania and Europe were more likely to exhibit the hVISA phenotype than isolates from the United States (77.8% and 35.0% vs 13.9%; P < .001). The prevalence of hVISA was higher among isolates with a vancomycin minimum inhibitory concentration of 2 mg/L (P = .026). hVISA-infected patients were more likely to have persistent bacteremia (68.4% vs 37.0%; P = .029) and heart failure (47.4% vs 19.6%; P = .033). Mortality did not differ between hVISA- and non-hVISA-infected patients (42.1% vs 34.8%, P = .586). hVISA and non-hVISA isolates were genotypically similar. CONCLUSIONS: In these analyses, the hVISA phenotype occurred in more than one-quarter of MRSA IE isolates, was associated with certain IE complications, and varied in frequency by geographic region.
BACKGROUND: The significance of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) is unknown. Using a multinational collection of isolates from methicillin-resistant S. aureus (MRSA) infective endocarditis (IE), we characterized patients with IE with and without hVISA, and we genotyped the infecting strains. METHODS: MRSA bloodstream isolates from 65 patients with definite IE from 8 countries underwent polymerase chain reaction (PCR) for 31 virulence genes, pulsed-field gel electrophoresis, and multilocus sequence typing. hVISA was defined using population analysis profiling. RESULTS: Nineteen (29.2%) of 65 MRSA IE isolates exhibited the hVISA phenotype by population analysis profiling. Isolates from Oceania and Europe were more likely to exhibit the hVISA phenotype than isolates from the United States (77.8% and 35.0% vs 13.9%; P < .001). The prevalence of hVISA was higher among isolates with a vancomycin minimum inhibitory concentration of 2 mg/L (P = .026). hVISA-infected patients were more likely to have persistent bacteremia (68.4% vs 37.0%; P = .029) and heart failure (47.4% vs 19.6%; P = .033). Mortality did not differ between hVISA- and non-hVISA-infected patients (42.1% vs 34.8%, P = .586). hVISA and non-hVISA isolates were genotypically similar. CONCLUSIONS: In these analyses, the hVISA phenotype occurred in more than one-quarter of MRSA IE isolates, was associated with certain IE complications, and varied in frequency by geographic region.
Authors: Steven J Campbell; Hitesh S Deshmukh; Charlotte L Nelson; In-Gyu Bae; Martin E Stryjewski; Jerome J Federspiel; Giang T Tonthat; Thomas H Rude; Steven L Barriere; Ralph Corey; Vance G Fowler Journal: J Clin Microbiol Date: 2007-12-12 Impact factor: 5.948
Authors: Francesc Marco; Cristina García de la Mària; Yolanda Armero; Eurídice Amat; Dolors Soy; Asunción Moreno; Ana del Río; Manel Almela; Carlos A Mestres; José M Gatell; María Teresa Jiménez de Anta; José M Miró Journal: Antimicrob Agents Chemother Date: 2008-04-21 Impact factor: 5.191
Authors: Tahaniyat Lalani; Jerome J Federspiel; Helen W Boucher; Thomas H Rude; In-Gyu Bae; Michael J Rybak; Giang T Tonthat; G Ralph Corey; Martin E Stryjewski; George Sakoulas; Vivian H Chu; Jeff Alder; Judith N Steenbergen; Steven A Luperchio; Marilyn Campion; Christopher W Woods; Vance G Fowler Journal: J Clin Microbiol Date: 2008-07-02 Impact factor: 5.948
Authors: T P Lodise; J Graves; A Evans; E Graffunder; M Helmecke; B M Lomaestro; K Stellrecht Journal: Antimicrob Agents Chemother Date: 2008-06-30 Impact factor: 5.191
Authors: Michael J Rybak; Steve N Leonard; Kerri L Rossi; Chrissy M Cheung; Helio S Sader; Helio S Sadar; Ronald N Jones Journal: J Clin Microbiol Date: 2008-07-16 Impact factor: 5.948
Authors: Warren E Rose; Steven N Leonard; Kerri L Rossi; Glenn W Kaatz; Michael J Rybak Journal: Antimicrob Agents Chemother Date: 2008-11-17 Impact factor: 5.191
Authors: Clare E Miller; Rahul Batra; Ben S Cooper; Amita K Patel; John Klein; Jonathan A Otter; Theodore Kypraios; Gary L French; Olga Tosas; Jonathan D Edgeworth Journal: Clin Infect Dis Date: 2011-12-20 Impact factor: 9.079
Authors: Carol L Moore; Paola Osaki-Kiyan; Marybeth Perri; Susan Donabedian; Nadia Z Haque; Anne Chen; Marcus J Zervos Journal: J Clin Microbiol Date: 2010-03-24 Impact factor: 5.948
Authors: J M Pericàs; J A Messina; C Garcia-de-la-Mària; L Park; B K Sharma-Kuinkel; F Marco; D Wray; Z A Kanafani; M Carugati; E Durante-Mangoni; P Tattevin; V H Chu; A Moreno; V G Fowler; J M Miró Journal: Clin Microbiol Infect Date: 2017-02-01 Impact factor: 8.067
Authors: Michael J Rybak; Celine Vidaillac; Helio S Sader; Paul R Rhomberg; Hossein Salimnia; Lawrence E Briski; Audrey Wanger; Ronald N Jones Journal: J Clin Microbiol Date: 2013-04-17 Impact factor: 5.948
Authors: Michael R Yeaman; Scott G Filler; Siyang Chaili; Kevin Barr; Huiyuan Wang; Deborah Kupferwasser; John P Hennessey; Yue Fu; Clint S Schmidt; John E Edwards; Yan Q Xiong; Ashraf S Ibrahim Journal: Proc Natl Acad Sci U S A Date: 2014-12-08 Impact factor: 11.205